Guard Therapeutics International AB

As of March 31, 2026, Guard Therapeutics International AB carries a market capitalization of 29.65M, placing it among publicly traded companies globally. Its enterprise value stands at -11.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Guard Therapeutics International AB's next confirmed earnings release is scheduled for August 20, 2026.

As of March 31, 2026, Guard Therapeutics International AB has 20.17M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Guard Therapeutics International AB maintains a current ratio of 7.13, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Guard Therapeutics International AB posted a negative return on equity (ROE) of -172.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -138.38, reflecting losses generated across the asset base.

As of the close on August 20, 2026, Guard Therapeutics International AB's stock has declined approximately 93.73% over the past 52 weeks. The 50-day moving average sits at 1.50, while the 200-day moving average is 1.48.

Over the twelve months ended March 31, 2026, Guard Therapeutics International AB generated - - in revenue and converted that into -80.99M in net income, yielding earnings per share of -4.05. EBITDA reached -80.98M, while operating income came in at -80.98M.

These figures are as of March 31, 2026. Total book value stands at 36.54M, with working capital of 38.69M providing operational flexibility.

Guard Therapeutics International AB produced -82.34M in operating cash flow over the twelve months ended March 31, 2026. After subtracting - - in capital expenditures, free cash flow totaled -82.34M - equivalent to -4.12 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -280.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -363.68, meaning Guard Therapeutics International AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Guard Therapeutics International AB's most recent stock split took place on March 17, 2025 with a 725:756 split ratio.

As of March 31, 2026, Guard Therapeutics International AB has an Altman Z-Score of -30.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.